Powder Vaccines for Pulmonary Delivery

Jin, Tom H.; Tsao, Eric

doi:10.1007/978-1-4614-5070-2_14

Cited by 5 publications

(1 citation statement)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Published studies on the scale-up of spray-dried vaccines to a commercial scale are relatively scarce due to confidentiality. Table 3 summarizes published studies by vaccine type, spray dryer model, scale-up factor, and temperature conditions [55][56][57][58][59][60][61][62]. For example, with a batch size of approximately 1 liter (11.2 w% solids in feed mix) and a high yield of >90%, a pilotscale Mobile Minor (GEA Niro) can produce sufficient powder for 5,000 to 10,000 doses of hepatitis B subunit vaccine [60].…”

Section: Fig 3 Predicted Design Space For Whole Inactivated Influenza...mentioning

confidence: 99%

Spray Drying of Vaccines A Review

Proceedings of the 22nd International Drying Symposium on Drying Technology - IDS '22

View full text Add to dashboard Cite

Most FDA-approved vaccines require cold storage at 2 to 8 °C, and some must even be frozen at colder temperatures to maintain their efficacy. The associated complex logistics of the cold chain for transport, distribution and storage make mass vaccination campaigns costly. There is also a risk of vaccines being wasted due to improper storage. In addition, almost all vaccines are administered by injection, which requires trained health workers, sterility, and proper disposal of sharps. An important strategy to prevent a pandemic is to stockpile stable vaccines for rapid intervention in the event of a disease outbreak. Drying technologies are suitable for producing thermostable vaccines. The conventional method for converting liquid vaccines into a thermostable dry solid form is freeze drying. In comparison, aseptic spray drying offers an economical alternative with fast drying, scalability, and high capacity to overcome bottlenecks in production. The stable powder form and particle design enable new routes of administration by inhalation, nasal, dermal, oral, or injection (after reconstitution). Challenges include thermal stress, residual moisture content, aseptic processing, and powder filling. This study provides a review of the current state of the art in stabilizing vaccines by spray drying.

show abstract